Bachelor of Pharmacy

Florida Cancer Specialists & Research Institute Shares Pharmacy Expertise To Advance Medically Integrated Oncology Care

Retrieved on: 
Wednesday, April 3, 2024
Real-World Evidence, RN, Success, BP, RRMM, Doctor of Pharmacy, BCPS, Selinexor, Incidence, Partnership, Physician, Manufacturing, Bachelor of Pharmacy, DNP, Nursing, Prior authorization, Pharmacist, Roger Hawkins (drummer), CAPM, MPA, BSN, Therapy, RPH, Pharmacy, Outcome, Safety, Infrared spectroscopy correlation table, Best practice, FCS, PACS, OCN, Data, Metric, Health care

FORT MYERS, Fla., April 3, 2024 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) leaders and pharmacy experts will share insights and best practices in specialty pharmacy operations and dispensing that are contributing to positive patient outcomes at the NCODA 2024 Spring Forum in Dallas. The focus of the multi-day gathering, "Driving Optimal Strategies for Patient Care in Medically Integrated Oncology," is on the vital role of pharmacy involvement throughout the entire cancer care continuum.

Key Points: 
  • The focus of the multi-day gathering, "Driving Optimal Strategies for Patient Care in Medically Integrated Oncology," is on the vital role of pharmacy involvement throughout the entire cancer care continuum.
  • "Our Rx To Go team members continue to set the standard of excellence for medically-integrated oncology pharmacy and support services," said FCS President & Managing Physician Lucio Gordan, MD .
  • "They are well-equipped to contribute top-tier knowledge to help steer the future of oncology care."
  • NCODA is a globally recognized not-for-profit organization dedicated to building a patient-centered, medically integrated community of health care providers whose focus is to innovate the continuity of cancer care so that every patient receives the maximum benefit from their cancer treatment.

ANGANY’s First Clinical Trial Concludes on Time and with Positive Results

Retrieved on: 
Monday, January 29, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Doctor of Philosophy, Bachelor of Pharmacy, Allergy, Clinical trial, Safety, Cat, Therapy

The study results were consistent throughout the 20 human adult cat allergic participants.

Key Points: 
  • The study results were consistent throughout the 20 human adult cat allergic participants.
  • The final results and conclusions of this clinical trial will be submitted to a major scientific journal.
  • ANGANY’s First-in-Human study of its novel biologic ANG-101 candidate vaccine against cat allergy concluded in December 2023, ahead of schedule.
  • The results should also be presented at the EAACI’s Annual Meeting to be held in Valencia in May 2024.

Florida Cancer Specialists & Research Institute Best Practices Program Improves Treatment Response and Survival for Patients with Multiple Myeloma

Retrieved on: 
Thursday, January 25, 2024
Real-World Evidence, Death, Incidence, RN, BSN, Bachelor of Pharmacy, Partnership, Survival, RRMM, Multiple myeloma, CAPM, Bone marrow, Data, FDA, Current Oncology, FCS, Doctor of Philosophy, RPH, OCN, BP, Infrared spectroscopy correlation table, Immune system, Nursing

FORT MYERS, Fla., Jan. 25, 2024 /PRNewswire/ -- A best practices program developed at Florida Cancer Specialists & Research Institute (FCS) has been shown to improve outcomes for adult patients prescribed selinexor for the treatment of relapsed/refractory multiple myeloma (RRMM).

Key Points: 
  • A real-world study by FCS authors details a program to improve patient outcomes for multiple myeloma.
  • Results obtained from a one-year retrospective observational study using data collected by FCS' Real-World Evidence team were recently published in Current Oncology.
  • He added, "Our findings, as detailed in this article, support the hypothesis that a best practices program designed around specific anticancer drugs can optimize prescribing practices, leading to better disease control and improvements in a patient's cancer care journey."
  • The FCS Real-World Evidence team works with internal and external partners providing insights to improve treatment decisions and clinical outcomes based on evidence generated using real-world data.

AllyGPO Taps Oncology Industry Veteran, Ray Bailey, as Strategic Advisor

Retrieved on: 
Tuesday, November 14, 2023
FCS, Patient, Pharmacist, GPO, Bailey, Cancer, System, SVP, Hospital, Nursing, Bachelor of Pharmacy

TEMPE, Ariz., Nov. 14, 2023 /PRNewswire/ -- AllyGPO, an umbrella of individual specialty group purchasing organizations (GPOs) exclusively serving community physician practices, is proud to announce Ray Bailey, BPharm, RPh, an expert in the clinical pharmacy management of cancer patients in the community setting, as an advisor in the launch of AllyOncology.

Key Points: 
  • Ray Bailey, BPharm, RPh, a thought leader in community oncology pharmacy and former SVP of Pharmacy Services at Florida Cancer Specialists, joins AllyGPO to advise on key oncology initiatives.
  • "We look forward to the valuable contributions Ray will make as we continue to innovate in the oncology GPO space."
  • Bailey is known throughout community oncology for his leadership, advocacy, business innovation, and "always put patients first" approach.
  • Prior to the oncology practice setting, Bailey worked for 24 years in the home infusion specialty pharmacy space.

ANGANY Appoints Christine Guillen as CEO, Announces Strengthening of Its Executive Committee

Retrieved on: 
Thursday, November 2, 2023
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Bachelor of Pharmacy, Drug, DMV, Executive Committee, Doctor of Pharmacy, Management

ANGANY announces the appointment of Christine Guillen, PharmD, as Chief Executive Officer.

Key Points: 
  • ANGANY announces the appointment of Christine Guillen, PharmD, as Chief Executive Officer.
  • In this capacity, Ms. Guillen will sit on the Board of Directors.
  • ANGANY also announces the strengthening of its Executive Committee with the appointment of Mr. Patrick Colin, BPharm PhD, as Vice-President, Clinical Development, and Pr.
  • Ms. Guillen says: "I'm delighted to take up the challenge of bringing a breakthrough technology to a tangible clinical and pharmaceutical reality.

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Retrieved on: 
Monday, October 23, 2023
Oncology, Health, Other Science, Pharmaceutical, Science, Biotechnology, Persephone, Allergy, United Kingdom, Veronica, Janssen, University of Nottingham, Amylin Pharmaceuticals, DSM-IV codes, Management, Diabetes, Acquisition, General partnership, Research, Infant, Trustee, Keck Graduate Institute, Marketing, Executive, Bristol Myers Squibb, University, Bachelor of Pharmacy, Education, Therapy, Intercept Pharmaceuticals, Pharmaceutical industry, Pharmacy

Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors.

Key Points: 
  • Persephone Biosciences Inc., a biotechnology company reimagining patient health through the development of microbiome-based medicines, today announced that it has appointed Daniel Bradbury as Chair of the Board of Directors.
  • Additionally, Persephone has a further two clinical studies underway, namely our ARGONAUT study of gut microbiome-linked immune modulation in cancer treatment response, and our AMBROSIA food-as-medicine study.
  • “As Chair, Dan brings his vast experience as a serial entrepreneur, spanning both public and private biotechs, to our company.
  • In addition, Mr. Bradbury serves on the Keck Graduate Institute’s Board of Trustees and the University of California San Diego’s Rady School of Management Dean’s Advisory Council.

World Leaders in Medically Integrated Oncology Set to Gather at NCODA's 2023 Summit to Further Elevate Patient Care

Retrieved on: 
Monday, October 23, 2023
NFL, World Leaders, Health, IEC, Heart, MD, Doctor of Philosophy, MBA, Harvard University, Master of Pharmacy, Physician, Health care, Pharmacy, Master of Science, Neurosurgery, Cancer, Florida State University, Nursing, Patient, Integration, Bachelor of Pharmacy, Pharmacist

ORLANDO, Fla., Oct. 23, 2023 /PRNewswire/ -- Physicians, nurses, pharmacists, and other important clinical and administrative team members, along with partnering pharmaceutical industry representatives from all over the world will gather in Orlando October 25-27 for the NCODA 2023 International Fall Summit to advance best practices and innovations in integrated cancer care. At the heart of the conference is the impact of medically integrated oncology and how coordination of care through a team of professionals is designed to ease the burden on patients and ensure that they feel supported and are receiving the best possible care from a wide range of oncology specialists.

Key Points: 
  • World Leaders in Medically Integrated Oncology Set to Gather at NCODA's 2023 Summit to Further Elevate Patient Care.
  • These leaders hail from a wide range of locations and healthcare systems, including Croatia, Morocco, Brazil, Japan, Canada, Sweden, and Greece.
  • Collaborating is at the heart of oncology and the integrated model, and the NCODA IEC is an example of that in practice."
  • It's an honor to work with the IEC and shine added focus on the collaboration of the international oncology pharmacist community in positively impacting patient care and clinical outcomes."

DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer

Retrieved on: 
Tuesday, September 12, 2023
FDA, Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Vaccine, DMAC, Duquesne University, Drug delivery, Pharmacy, Stroke, CMC, DSM-IV codes, MedImmune, Human Genome Sciences, AstraZeneca, Bristol Myers Squibb, Bachelor of Pharmacy, Patient, University of Mumbai, Approved Drug Products with Therapeutic Equivalence Evaluations, Mercer University, Pharmaceutical industry, Science, GSK plc, Pfizer

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Ambarish Shah, Ph.D. as Chief Technology Officer.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Ambarish Shah, Ph.D. as Chief Technology Officer.
  • Dr. Shah will lead the development of DiaMedica’s manufacturing operations for the late-stage drug candidate DM199.
  • “I am delighted to join DiaMedica at this pivotal time in the Company’s advancement,” said Dr. Shah.
  • He obtained his doctorate in Pharmaceutical Sciences from Mercer University, Atlanta, Georgia with a focus on Drug Delivery.

Study Confirms Effectiveness of Trilaciclib for Treatment of Patients with Extensive-Stage Small Cell Lung Cancer Co-authored by Florida Cancer Specialists & Research Institute Physicians and Senior Leaders

Retrieved on: 
Monday, July 31, 2023
BCPS, CIM, Doctor of Pharmacy, Senior, Trilaciclib, FACP, Cancer, Lung cancer, Hope, Research, Doctor of Philosophy, Pharmacist, SCLC, Bone marrow, Patient, Physician, Manuscript, Data, FDA, FCS, Pharmaceutical industry, Medical imaging, Medical device, Bachelor of Pharmacy, MD

FORT MYERS, Fla., July 31, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) physicians and senior leaders are co-authors of a study that confirms the effectiveness of trilaciclib for the treatment of adult patients with Extensive-Stage Small Cell Lung Cancer. Trilaciclib is the first FDA-approved therapy in its class to help protect bone marrow cells from damage caused by chemotherapy.

Key Points: 
  • FORT MYERS, Fla., July 31, 2023 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) physicians and senior leaders are co-authors of a study that confirms the effectiveness of trilaciclib for the treatment of adult patients with Extensive-Stage Small Cell Lung Cancer.
  • Trilaciclib is the first FDA-approved therapy in its class to help protect bone marrow cells from damage caused by chemotherapy.
  • The abstract, Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy, was recently published in the journal, Advances in Therapy.
  • "Our study evaluated real-world outcomes of patients using data from published and unpublished studies of trilaciclib and comparable non-trilaciclib-treated patients," said Dr. Hart.

KidneyIntelX™ Clinical Decision Impact / Validation and Health Economic Data to be Presented at Upcoming Scientific Conferences

Retrieved on: 
Thursday, June 15, 2023
American Association of Nurse Practitioners, Bachelor of Pharmacy, Abstract, LSE, Endocrinology, American Diabetes Association, Doctor of Pharmacy, University, Nephrology, Type 2 diabetes, PDT, Emergency Pharmacy System, SALT, Assistant, Chicago, Patient, Division, Physician, Diabetic nephropathy, Risk, Motivation, Poster, DKD, American Association of Clinical Endocrinologists, Health, Mount Sinai Health System, CKD, Irene, AANP, Conference, Kidney disease, Medicine, D3M, Pharmaceutical industry, Medical device, Nursing, Policy

Accepted abstracts reflect the growing body of scientific evidence demonstrating the important role KidneyIntelX serves towards advancing patient care and awareness for early-stage diabetic kidney disease.

Key Points: 
  • Accepted abstracts reflect the growing body of scientific evidence demonstrating the important role KidneyIntelX serves towards advancing patient care and awareness for early-stage diabetic kidney disease.
  • The presentations at the American Diabetes Association 83rd Scientific Sessions meeting include late-breaking data from a multi-year real-world evidence study, extended validation of KidneyIntelX, and a cost-effectiveness analysis addressing economic benefit in the VA population.
  • American Diabetes Association 83rd Scientific Sessions presentations will be displayed over three days June 24-26, 2023, and moderated at the specified times below.
  • For more information about Renalytix hosted medical education events while at the 83rd Scientific Sessions of the American Diabetes Association, please email [email protected] .